postdoctoral position in the team of Dr. Mario Amendola in Genethon, biopark of Evry.
This project deals with neuromuscular and musculoskeletal disorders, which are amongst the most frequent causes of disability in Europe. These genetic diseases are characterized by severe skeletal muscle wasting, impaired mobility, reduction of quality of life and premature death. Although supportive treatments are in clinical practice to manage symptoms, there is still no cure for muscular dystrophies. Thus, the overarching objective of our project is the generation of innovative models of human skeletal muscle disorders to develop, screen and validate new neuromuscular gene therapy vectors and genome editing strategies with high efficacy and selective tropism coupledwith low toxicity and limited immunogenicity.